Last reviewed · How we verify

NCT06749431

Clinical Outcomes, Graft Longevity, and Chondral Protection Following Primary or Revision Meniscal Allograft Transplantation Surgery

ENROLLING BY INVITATION Last updated 27 December 2024
What this trial tests

trial in Meniscus Tear in 5,000 participants. Enrolling by invitation.

Timeline
5 January 2025
Primary endpoint
5 January 2030
5 January 2050

Quick facts

Lead sponsorJoint Restoration Foundation, Inc.
StatusENROLLING BY INVITATION
Study typeOBSERVATIONAL
Enrollment5,000
Start date5 January 2025
Primary completion5 January 2030
Estimated completion5 January 2050
Sites1 location across United States

Conditions studied

Sponsor

Joint Restoration Foundation, Inc.

Who can join

Adults 10 to 65, any sex, with Meniscus Tear or Meniscus Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The MERCuRE (MEniscus, REstoration, Conservation, and Repair) group is embarking on a 20-year follow-up study to evaluate the clinical outcomes, graft longevity, and chondral protection following primary or revision Meniscal Allograft Transplantation surgery This clinical investigation is a prospective, primary observational, open-label, non-randomized, multi-center study. It is designed to collect clinical follow-up data on patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Meniscus Tear

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06749431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing